JP5627705B2 - 聴力損傷および目まいの治療用のβ−カルボリン - Google Patents

聴力損傷および目まいの治療用のβ−カルボリン Download PDF

Info

Publication number
JP5627705B2
JP5627705B2 JP2012546361A JP2012546361A JP5627705B2 JP 5627705 B2 JP5627705 B2 JP 5627705B2 JP 2012546361 A JP2012546361 A JP 2012546361A JP 2012546361 A JP2012546361 A JP 2012546361A JP 5627705 B2 JP5627705 B2 JP 5627705B2
Authority
JP
Japan
Prior art keywords
carboline
methyl
cyclo
och
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012546361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515752A (ja
JP2013515752A5 (enExample
Inventor
ハンス ロンメルスパッヒャー
ハンス ロンメルスパッヒャー
Original Assignee
アウディオキュア ファーマ ゲーエムベーハー
アウディオキュア ファーマ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アウディオキュア ファーマ ゲーエムベーハー, アウディオキュア ファーマ ゲーエムベーハー filed Critical アウディオキュア ファーマ ゲーエムベーハー
Publication of JP2013515752A publication Critical patent/JP2013515752A/ja
Publication of JP2013515752A5 publication Critical patent/JP2013515752A5/ja
Application granted granted Critical
Publication of JP5627705B2 publication Critical patent/JP5627705B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012546361A 2009-12-28 2010-12-28 聴力損傷および目まいの治療用のβ−カルボリン Active JP5627705B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102009060811 2009-12-28
DE102009060811.7 2009-12-28
US28239510P 2010-02-02 2010-02-02
US61/282,395 2010-02-02
PCT/DE2010/001530 WO2011079841A1 (de) 2009-12-28 2010-12-28 Beta-carboline zur behandlung von hörschäden und schwindel

Publications (3)

Publication Number Publication Date
JP2013515752A JP2013515752A (ja) 2013-05-09
JP2013515752A5 JP2013515752A5 (enExample) 2013-10-24
JP5627705B2 true JP5627705B2 (ja) 2014-11-19

Family

ID=44246908

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546361A Active JP5627705B2 (ja) 2009-12-28 2010-12-28 聴力損傷および目まいの治療用のβ−カルボリン

Country Status (17)

Country Link
US (1) US9107914B2 (enExample)
EP (1) EP2519238B1 (enExample)
JP (1) JP5627705B2 (enExample)
KR (1) KR20120098855A (enExample)
CN (1) CN102844029A (enExample)
AU (1) AU2010338669A1 (enExample)
BR (1) BR112012015967B1 (enExample)
CA (1) CA2785233C (enExample)
DE (1) DE112010005017A5 (enExample)
IL (1) IL220661A (enExample)
IN (1) IN2012DN05066A (enExample)
MX (1) MX2012007678A (enExample)
NZ (1) NZ600478A (enExample)
RU (1) RU2012132429A (enExample)
SG (1) SG181599A1 (enExample)
WO (1) WO2011079841A1 (enExample)
ZA (1) ZA201204476B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3184040A1 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Compositions and methods for epithelial stem cell expansion comprising a wnt agonist and a histone deacetylase inhibitor
DK2968284T3 (da) 2013-03-14 2021-06-14 Osteoqc Inc Alkyl-amin-harminderivater til fremme af knoglevækst
EP2853533A1 (de) * 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin
WO2016037016A1 (en) 2014-09-03 2016-03-10 The Brigham And Women's Hospital, Inc. Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
AU2017205194A1 (en) 2016-01-08 2018-07-19 Massachusetts Institute Of Technology Production of differentiated enteroendocrine cells and insulin producing cells
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
EP3321264A1 (en) * 2016-11-14 2018-05-16 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Selective inhibitors of genotoxic stress-induced ikk/nf-kb pathways
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
CN112996506A (zh) 2018-08-14 2021-06-18 奥斯特克有限公司 吡咯并二吡啶化合物
BR112021002655A2 (pt) 2018-08-14 2021-05-04 Osteoqc Inc. compostos flúor ss-carbolina
WO2020037326A1 (en) 2018-08-17 2020-02-20 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating foxo
US11162071B2 (en) 2018-08-17 2021-11-02 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating JAG-1
EP3849530A4 (en) * 2018-09-12 2022-06-22 Hough Ear Institute Methods for treating hearing loss incident to cochlear implant surgery
EP3772515A1 (en) * 2019-08-09 2021-02-10 Audiocure Pharma GmbH Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3240514A1 (de) 1982-10-29 1984-05-03 Schering AG, 1000 Berlin und 4709 Bergkamen Ss-carboline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US20040038970A1 (en) 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
CN1169808C (zh) * 1998-06-12 2004-10-06 研究及应用科学协会股份有限公司 β-咔啉化合物
US20050143371A1 (en) * 2003-07-23 2005-06-30 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
DE102007009264A1 (de) 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen

Also Published As

Publication number Publication date
EP2519238A1 (de) 2012-11-07
CN102844029A (zh) 2012-12-26
KR20120098855A (ko) 2012-09-05
CA2785233A1 (en) 2011-06-07
CA2785233C (en) 2018-10-09
ZA201204476B (en) 2014-01-29
MX2012007678A (es) 2012-09-12
SG181599A1 (en) 2012-07-30
BR112012015967A2 (pt) 2016-04-19
NZ600478A (en) 2013-10-25
EP2519238B1 (de) 2014-08-13
US20130028958A1 (en) 2013-01-31
BR112012015967B1 (pt) 2019-08-27
IN2012DN05066A (enExample) 2015-10-09
RU2012132429A (ru) 2014-02-10
WO2011079841A1 (de) 2011-07-07
AU2010338669A1 (en) 2012-06-21
IL220661A0 (en) 2012-08-30
JP2013515752A (ja) 2013-05-09
IL220661A (en) 2016-03-31
DE112010005017A5 (de) 2012-10-04
US9107914B2 (en) 2015-08-18

Similar Documents

Publication Publication Date Title
JP5627705B2 (ja) 聴力損傷および目まいの治療用のβ−カルボリン
US10844061B2 (en) Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous system
TWI750218B (zh) sGC 刺激劑
US20250243201A1 (en) Organic compounds
US9630964B2 (en) Fluoro-9-methyl-β-carbolines
JPWO2007046456A1 (ja) 新規水溶性プロドラッグを含有する、膵臓癌、卵巣癌または肝臓癌の予防または治療剤
WO2009110526A1 (ja) ３’，５－ジ－２－プロペニル－（１，１’－ビフェニル）－２，４’－ジオールを有効成分として含有する視神経障害の予防又は治療剤
HK1222844B (en) FLUOR-9-METHY-β-CARBOLINES
US20110319463A1 (en) Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
HK1164884A (en) Prophylactic or therapeutic agent for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivative or salt thereof as active ingredient

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140902

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140930

R150 Certificate of patent or registration of utility model

Ref document number: 5627705

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250